Report cover image

U.S. Induced Pluripotent Stem Cells (iPSCs) Market - Industry Trends and Forecast to 2031

Publisher Data Bridge Market Research
Published Dec 01, 2023
Length 100 Pages
SKU # DAABD18458996

Description

U.S. Induced Pluripotent Stem Cells (iPSCs) Market - Industry Trends and Forecast to 2031


The U.S. induced pluripotent stem cells (iPSCs) market is expected to reach USD 488.42 million by 2031 from USD 218.87 million in 2023, growing at a CAGR of 10.7% in the forecast period of 2024 to 2031.

Market Segmentation
U.S. Induced Pluripotent Stem Cells (iPSCs) Market, By Model Type (ECM-Patterned PAA/ PDMS Substrates, Microgroove PDMS Substrates, Strained Membranes, 3D Sacffolds, Free-Floating Hydrogel Contructs, and EHTS), Material (Natural Hydrogel Based Cardiac Models and Synthetic Fibrous Cardiac Models), Cell Source (Skin Cells and Blood Cells), Dimensional Type (2D and 3D), Application (Production of New Cardiac Tissue To Replace Tissue Destroyed By Infraction Or Other Diseases, Heart Failure, Ischemic Heart Disease, Arrhythmia, Cardiomyopathies, Valvular Heart Disease, Heart Disease Screening, and Others), End Use (Pharmaceutical & Biotechnology Companies, Academic and Government Research Institutes, Contract Development & Manufacturing Organizations, and Others ), Distribution Channel (Direct Tender and Retail Sales) Country (U.S.) – Industry Trends and Forecast to 2031

Overview of U.S. Induced Pluripotent Stem Cells (iPSCs) Market Dynamics

Driver

• Technological advancement in regenerative medicine
Restrain

• Safety concerns and technical difficulties

Opportunity

• Increasing interest in personalized medicine

Market Players

Some of the major market players operating in the U.S. induced pluripotent stem cells (iPSCs) market are:

• Corning Incorporated
• Lonza
• MIMETAS
• CN Bio Innovations Ltd
• 3D BIOTEK LLC
• AXOL
• REPROCELL Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.

Table of Contents

100 Pages
1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of U.S. Induced Pluripotent Stem Cells (Ipscs) Market
1.4 Currency And Pricing
1.5 Limitations
1.6 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 Years Considered For The Study
2.3 Dbmr Tripod Data Validation Model
2.4 Primary Interviews With Key Opinion Leaders
2.5 Dbmr Market Position Grid
2.6 Multivariate Modelling
2.7 Type Lifeline Curve
2.8 Market End User Coverage Grid
2.9 Secondary Sources
2.10 Assumptions
3 Executive Summary
4 Premium Insights
4.1 Pestel Analysis
4.2 Porter’s Five Forces
5 Market Overview
5.1 Drivers
5.1.1 Technological Advancement In Regenerative Medicine
5.1.2 Expanding Applications In Drugs Discovery
5.2 Restraints
5.2.1 Safety Concerns And Technical Difficulties
5.2.2 Competition And Intellectual Property Issues
5.3 Opportunities
5.3.1 Increasing Interest Of Personalized Medicine
5.3.2 Increasing Adoption Of Stem Cell Therapy
5.4 Challenge
5.4.1 High Cost Associated With Stem Cell Therapies
6 U.S. Induced Pluripotent Stem Cells (Ipscs) Market, By Model Type
6.1 Overview
6.2 Ecm Patterned Paa/Pdms Substrates
6.3 Microgroove Pdms Substrates
6.4 Strained Membranes
6.5 3d Sacffolds
6.6 Free-floating Hydrogel Contructs
6.7 Ehts
7 U.S. Induced Pluripotent Stem Cells (Ipscs) Market, By Material
7.1 Overview
7.2 Natural Hydrogel- Based Cardiac Models
7.3 Synthetics Fibrous Cardiac Models
7.3.1 Polyglycolic Acid (Pga)
7.3.2 Poly E-caprolactone (Pcl)
7.3.3 Polyurethane
7.3.4 Polylactic Acid (Pla)
7.3.5 Others
8 U.S. Induced Pluripotent Stem Cells (Ipscs) Market, By Cell Source
8.1 Overview
8.2 Skin Cells
8.2.1 Fibroblast
8.2.2 Keratinocytes
8.2.3 Melanocytes
8.2.4 Neural Stem Cells
8.2.5 Adipose Derive Stem Cells
8.2.6 Others
8.3 Blood Cells
8.3.1 Peripheral Blood Monoclear Cells
8.3.2 Cord Blood Endothelial Cells
8.3.3 Cord Blood Stem Cells
8.3.4 Others
9 U.S. Induced Pluripotent Stem Cells (Ipscs) Market, By Dimensional Type
9.1 Overview
9.2 3d
9.3 Skin Cells
9.3.1 Fibroblast
9.3.2 Keratinocytes
9.3.3 Melanocytes
9.3.4 Neural Stem Cells
9.3.5 Adipose Derive Stem Cells
9.3.6 Others
9.4 Blood Cells
9.4.1 Peripheral Blood Monoclear Cells
9.4.2 Cord Blood Endothelial Cells
9.4.3 Cord Blood Stem Cells
9.4.4 Others
9.5 2d
9.5.1 Skin Cells
9.5.1.1 Fibroblast
9.5.1.2 Keratinocytes
9.5.1.3 Melanocytes
9.5.1.4 Neural Stem Cells
9.5.1.5 Adipose Derive Stem Cells
9.5.1.6 Others
9.5.2 Blood Cells
9.5.2.1 Peripheral Blood Monoclear Cells
9.5.2.2 Cord Blood Endothelial Cells
9.5.2.3 Cord Blood Stem Cells
9.5.2.4 Others
10 U.S. Induced Pluripotent Stem Cells (Ipscs) Market, By Application
10.1 Overview
10.2 Production Of New Cardiac Tissue To Replace Tissues Destroyed By Infraction Or Other Diseases
10.3 Heart Failure
10.4 Ischemic Heart Disease
10.5 Arrythmia
10.6 Cardiomyopathies
10.7 Valvular Heart Disease
10.8 Heart Disease Screening
10.9 Others
11 U.S. Induced Pluripotent Stem Cells (Ipscs) Market, By End Use
11.1 Overview
11.2 Pharmaceutical & Biotechnology Companies
11.3 Academic And Government Research Institutes
11.4 Contract Development & Manufacturing Organizations
11.5 Others
12 U.S. Induced Pluripotent Stem Cells (Ipscs) Market, By Distribution Channel
12.1 Overview
12.2 Direct Tender
12.3 Retail Sales
13 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: Company Landscape
13.1 Company Share Analysis: U.S.
14 Swot Analysis
15 Company Profile
15.1 Corning Incrporated
15.1.1 Company Snapshot
15.1.2 Revenue Analysis
15.1.3 Product Portfolio
15.1.4 Recent Development
15.2 Lonza
15.2.1 Company Snapshot
15.2.2 Revenue Analysis
15.2.3 Product Portfolio
15.2.4 Recent Development
15.3 Mimetas
15.3.1 Company Snapshot
15.3.2 Product Portfolio
15.3.3 Recent Development
15.4 Reprocell Inc.
15.4.1 Company Snapshot
15.4.2 Product Portfolio
15.4.3 Recent Development
15.5 Cn Bio Innovations
15.5.1 Company Snapshot
15.5.2 Product Portfolio
15.5.3 Recent Development
15.6 Axol Bioscience Ltd.
15.6.1 Company Snapshot
15.6.2 Product Portfolio
15.6.3 Recent Development
15.7 3d Biotek Llc.
15.7.1 Company Snapshot
15.7.2 Product Portfolio
15.7.3 Recent Development
16 Questionnaire
17 Related Reports
List Of Tables
Table 1 U.S. Induced Pluripotent Stem Cells (Ipscs) Market, By Model Type, 2022- 2031 (Usd Million)
Table 2 U.S. Induced Pluripotent Stem Cells (Ipscs) Market, By Material, 2022- 2031 (Usd Million)
Table 3 U.S. Synthetic Fibrous Cardiac Models Induced Pluripotent Stem Cells (Ipscs) Market, By Material, 2022-2031 (Usd Million)
Table 4 U.S. Induced Pluripotent Stem Cells (Ipscs) Market, By Cell Source, 2022- 2031 (Usd Million)
Table 5 U.S. Skin Cells In Induced Pluripotent Stem Cells (Ipscs) Market, By Cell Source, 2022- 2031 (Usd Million)
Table 6 U.S. Blood Cells In Induced Pluripotent Stem Cells (Ipscs) Market, By Cell Source, 2022- 2031 (Usd Million)
Table 7 U.S. Induced Pluripotent Stem Cells (Ipscs) Market, By Dimensional Type, 2022- 2031 (Usd Million)
Table 8 U.S. 3d In Induced Pluripotent Stem Cells (Ipscs) Market, By Cell Source, 2022-2031 (Usd Million)
Table 9 U.S. Skin Cells In Induced Pluripotent Stem Cells (Ipscs) Market, By Cell Source, 2022- 2031 (Usd Million)
Table 10 U.S. Blood Cells In Induced Pluripotent Stem Cells (Ipscs) Market, By Cell Source, 2022- 2031 (Usd Million)
Table 11 U.S. 2d In Induced Pluripotent Stem Cells (Ipscs) Market, By Cell Source, 2022- 2031 (Usd Million)
Table 12 U.S. Skin Cells In Induced Pluripotent Stem Cells (Ipscs) Market, By Cell Source, 2022- 2031 (Usd Million)
Table 13 U.S. Blood Cells In Induced Pluripotent Stem Cells (Ipscs) Market, By Cell Source, 2022- 2031 (Usd Million)
Table 14 U.S. Induced Pluripotent Stem Cells (Ipscs) Market, By Application, 2022- 2031 (Usd Million)
Table 15 U.S. Induced Pluripotent Stem Cells (Ipscs) Market, By End Use, 2022- 2031 (Usd Million)
Table 16 U.S. Induced Pluripotent Stem Cells (Ipscs) Market, By Distribution Channel, 2022- 2031 (Usd Million)
List Of Figures
Figure 1 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: Segmentation
Figure 2 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: Data Triangulation
Figure 3 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: Droc Analysis
Figure 4 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: Country Vs Regionalmarket Analysis
Figure 5 U.S. Induced Pluripotent Stem Cells (Ipscs)Market: Company Research Analysis
Figure 6 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: Interview Demographics
Figure 7 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: Dbmr Market Position Grid
Figure 8 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: Market End User Coverage Grid
Figure 9 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: Segmentation
Figure 10 Increasing Technological Advancement In Regenrative Medicine Is Driving The Growth Of U.S. Induced Pluripotent Stem Cells (Ipscs) Market In The Forecast Period Of 2024 To 2031
Figure 11 Model Type Segment Is Expected To Account For The Largest Share Of The U.S. Induced Pluripotent Stem Cells (Ipscs) Marketin 2024 & 2031
Figure 12 Drivers, Restraints, Opportunities, And Challenges Of U.S. Induced Pluripotent Stem Cells (Ipscs) Market
Figure 13 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Model Type, 2023
Figure 14 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Model Type, 2024-2031 (Usd Million)
Figure 15 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Model Type, Cagr (2024-2031)
Figure 16 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Model Type, Lifeline Curve
Figure 17 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Material, 2023
Figure 18 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Material, 2024-2031 (Usd Million)
Figure 19 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Material, Cagr (2024-2031)
Figure 20 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Material, Lifeline Curve
Figure 21 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Cell Source, 2023
Figure 22 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Cell Source, 2024-2031 (Usd Million)
Figure 23 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Cell Source, Cagr (2024-2031)
Figure 24 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Cell Source, Lifeline Curve
Figure 25 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Dimensional Type, 2023
Figure 26 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Dimensional Type, 2024-2031 (Usd Million)
Figure 27 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Dimensional Type, Cagr (2024-2031)
Figure 28 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Dimensional Type, Lifeline Curve
Figure 29 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Application, 2023
Figure 30 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Application, 2024-2031 (Usd Million)
Figure 31 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Application, Cagr (2024-2031)
Figure 32 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Application, Lifeline Curve
Figure 33 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By End Use, 2023
Figure 34 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By End Use, 2024-2031 (Usd Million)
Figure 35 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By End Use, Cagr (2024-2031)
Figure 36 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By End Use, Lifeline Curve
Figure 37 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Distribution Channel, 2023
Figure 38 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Distribution Channel, 2024-2031 (Usd Million)
Figure 39 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Distribution Channel, Cagr (2024-2031)
Figure 40 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: By Distribution Channel, Lifeline Curve
Figure 41 U.S. Induced Pluripotent Stem Cells (Ipscs) Market: Company Share 2023 (%)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us